Strategies for treating HIV-related lipodystrophy.
HIV-related lipodystrophy has emerged as one of the most prevalent problems for patients with HIV, since this infection can now be seen as a chronic disease. Despite its growing importance, crucial issues such as aetiopathogenesis, diagnosis, prevention and therapy remain largely unknown and unexplored. Current evidence suggests that aetiology is multifactorial. HIV infection, antiretroviral therapy and patient-related factors probably all contribute to the development of lipodystrophy. The lack of a formal definition and the nature of wasting syndromes that affect HIV-infected patients can hinder the diagnosis and treatment of lipodystrophy. Body fat changes have a major negative impact on the quality of life of patients. Metabolic abnormalities are also well known cardiovascular risk factors that can increase the morbidity and mortality due to cardiovascular disorders in a relatively young population. As yet, we do not know whether lipodystrophy is preventable or reversible. Several therapeutic approaches have been tested with limited success, however potential complications must be considered. These therapeutic approaches include general health measures (diet, exercise and discontinuation of smoking), switching antiretrovirals (from protease inhibitors to non-nucleoside reverse transcriptase inhibitors or abacavir, or from stavudine to other nucleoside reverse transcriptase inhibitors) and use of drugs with metabolic effects (metformin, thiazolidinediones, recombinant growth hormone and anabolic steroids). A judicious use of available data, and opting for an individualised approach seems the best option for management of this problem at present.
García-Viejo
M A
MA
Infectious Diseases Unit, Clinical Institute of Infectious Diseases and Immunology, IDIBAPS-Hospital Clinic University, C/Villarroel, 170, E-08036-Barcelona, Spain.
Ruíz
M
M
Martínez
E
E
D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects; D001823:Body Composition / Q000187:drug effects; D015658:HIV Infections / Q000150:complications* / Q000378:metabolism; D019247:HIV Wasting Syndrome / Q000188:drug therapy; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008060:Lipodystrophy / Q000188:drug therapy* / Q000209:etiology*
D019380:Anti-HIV Agents; D000960:Hypolipidemic Agents